Loading data
CVSANYSE
| Unit: USD | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.95 bn USD | 1.79 bn USD | 1.58 bn USD | 1.45 bn USD | 1.38 bn USD |
| Cost of revenue | 833.66 m USD | 771.43 m USD | 698.55 m USD | 648.49 m USD | 659.78 m USD |
| Selling, general and administrative expense | 730.72 m USD | 672 m USD | 632.97 m USD | 586.01 m USD | 566.49 m USD |
| Operating profit | 383.38 m USD | 341.54 m USD | 217.05 m USD | 168.17 m USD | 76.75 m USD |
| Interest expense | 45.44 m USD | 52.32 m USD | 63.66 m USD | 63.1 m USD | 129.35 m USD |
| Profit before tax | 345.12 m USD | 298.51 m USD | 163.94 m USD | 112.04 m USD | -51.49 m USD |
| Income tax expense | 77.74 m USD | 65.84 m USD | 26.22 m USD | 10.28 m USD | -15.54 m USD |
| Net income (reported basis) | 251.57 m USD | 237.07 m USD | 136.78 m USD | 93.36 m USD | 310.99 m USD |
| Basic earnings per share | 7.18 USD/share | 6.39 USD/share | 3.47 USD/share | 2.08 USD/share | 6.43 USD/share |
| Diluted earnings per share | 7.04 USD/share | 6.18 USD/share | 3.39 USD/share | 2.05 USD/share | 6.43 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.